

Bibliografia

- Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023). Psychedelic commercialization: A wide-spanning overview of the emerging psychedelic industry. *Psychiatric Medicine*, 1(3), 150-165.
- Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K., & Davoli, C. C. (2021). Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects. *ACS Pharmacology & Translational Science*, 4(2), 424-435.
- Aixalà, M. (2022). *Psychedelic integration: Psychotherapy for non-ordinary states of consciousness*. Synergetic Press.
- Andersen, K. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. *Acta Psychiatrica Scandinavica*, 143(2), 101-118.
- Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. *Personality and individual differences*, 117, 155-160.
- Bartlett, C. W., Klammer, B. G., Buyske, S., Petrill, S. A., & Ray, W. C. (2019). Forming big datasets through latent class concatenation of imperfectly matched databases features. *Genes*, 10(9).
- Bender, D., & Hellerstein, D. J. (2022). Assessing the risk-benefit profile of classical psychedelics: A clinical review of secondwave psychedelic research. *Psychopharmacology*, 1-26.
- Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. *Journal of Psychopharmacology*, 30(12), 1268-1278.
- Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. *Pharmacological Reviews*, 71(3), 316-344.
- Carhart-Harris, R. L., & Nutt, D. J. (2013). Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. *Journal of Psychoactive Drugs*, 45(4), 322-328.
- Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. *Journal of Psychopharmacology*, 32(7), 725-731.
- CBOS - Centrum Badań Opinii Społecznej (2021). *Młodzież 2021. Materiały prasowe – wybrane wyniki*. Warszawa: Krajowe Centrum Przeciwdziałania Uzależnieniom.
- Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. *Journal of Contextual Behavioral Science*, 15, 39-45.
- de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023). Systematic review of psychometric instruments used in research with psychedelics. *Journal of Psychoactive Drugs*, 55(3), 359-368.
- Doyle, M. A., Ling, S., Lui, L. M., Fragnelli, P., Teopiz, K. M., Ho, R., ... & McIntyre, R. S. (2022). Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. *Expert Opinion on Drug Safety*, 21(6), 733-743.
- EMCDDA – Europejskie Centrum Monitorowania Narkotyków i Narkomanii (2022). *Europejski raport narkotykowy 2022: Tendencje i osiągnięcia*. Urząd Publikacji Unii Europejskiej, Luksemburg.
- Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., ... & Prideaux, E. (2023). Extended difficulties following the use of psychedelic drugs: A mixed methods study. *PLoS One*, 18(10), e0293349.
- Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022). The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. *Frontiers in Psychology*, 13, 863247.
- Głuszczyk, K.M. (2023). *Psylocybina: magiczne / święte grzyby psylocybinowe, psychodeliczne lekarstwo natury*. Polska: niezależne wydawnictwo.
- Gręń, J., Kirouac, M., Pearson, M. R., & Ostaszewski, K. (2024). Exploring patterns of polysubstance use among young adults: a latent profile analysis. *Drugs: Education, Prevention and Policy*, 1-9.
- Gręń, J., Ostaszewski, K. (2023d). Behawioralne strategie chroniące związane z używaniem substancji psychoaktywnych w różnych kontekstach i populacjach. Przegląd literatury. *Alkoholizm i Narkomania*, 36(2).
- Gręń, J., Ostaszewski, K., Pearson, M. R. (2023b). Resilience through Harm Reduction? Protective Behavioral Strategies as a Factor of Resilience among Young Adults Using Various Psychoactive Substances. *Journal of Psychoactive Drugs*, 56(5), 689-698.
- Gręń, J., Ostaszewski, K., Wiczorek, Ł., Dąbrowska, K. (2022). "It'll Never Be Safe, But You Can Limit the Harms". Exploring Adolescents' Strategies to Reduce Harms Associated with Psychoactive Substance Use. *Substance Use & Misuse*, 57(3), 380-391.
- Gręń, J., Richards, D. K., Pearson, M. R., & Ostaszewski, K. (2023a). Development and validation of the Substance Use Protective Strategies Scale (SUPSS) among Polish young adults using various psychoactive substances. *International Journal of Drug Policy*, 104216.
- Gręń, J., Tyłś, F., Lasocik, M., Kiraly, C. (2023c). Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists. *Frontiers in Psychology*, 14, 1054692.
- Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*, 187, 268-283.
- Hartogsohn, I. (2022). Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture. *Transcultural psychiatry*, 59(5), 579-591.
- Hearne, E., & Van Hout, M. C. (2016). "Trip-sitting" in the black hole: a netnographic study of dissociation and indigenous harm reduction. *Journal of Psychoactive Drugs*, 48(4), 233-242.
- Herrmann, Z., Earleywine, M., De Leo, J., Slabaugh, S., Kenny, T., & Rush, A. J. (2023). Scoping review of experiential measures from psychedelic research and clinical trials. *Journal of Psychoactive Drugs*, 55(4), 501-517.
- Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. *Journal of Psychopharmacology*, 22(6), 603-620.
- Killion, B., Hai, A. H., Alsolami, A., Vaughn, M. G., Oh, P. S., & Salas-Wright, C. P. (2021). LSD use in the United States: Trends, correlates, and a typology of use. *Drug and Alcohol Dependence*, 223, 108715.
- Lorenc, M. (2019). *Czy psychodeliki uratują świat?* Warszawa: Krytyka Polityczna
- Lorenc, M. (2023). *Grzybobranie. Kulturowa historia psylocybiny*. Warszawa: Krytyka Polityczna.
- McAlpine, R. G., Blackburne, G., & Kamboj, S. K. (2024). Development and psychometric validation of a novel scale for measuring 'psychedelic preparedness'. *Scientific Reports*, 14(1), 3280.
- Mian, M. N., Altman, B. R., Low, F., & Earleywine, M. (2024). Development of the Protective Strategies for Psychedelics Scale: A novel

- inventory to assess safety strategies in the context of psychedelics. *Journal of psychopharmacology*, 38(1), 101-109.
- Moskalewicz, J., Wciórka, J. (2021). *Kondycja psychiczna mieszkańców Polski. Raport z badań „Kompleksowe badanie stanu zdrowia psychicznego społeczeństwa i jego uwarunkowań – EZOP II”*. Warszawa: Instytut Psychiatrii i Neurologii.
- Móró, L., Simon, K., Bárd, I., & Rácz, J. (2011). Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. *Journal of Psychoactive Drugs*, 43(3), 188-198.
- Nichols, D. E. (2016). Psychedelics. *Pharmacological Reviews*, 68(2), 264-355.
- Nichols, D. E., Nichols, C. D., & Hendricks, P. S. (2023). Proposed consensus statement on defining psychedelic drugs. *Psychiatric Medicine*, 1(1), 12-13.
- Olson, D. E. (2020). The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. *ACS Pharmacology & Translational Science*, 4(2), 563-567.
- Ona, G. (2018). Inside bad trips: Exploring extra-pharmacological factors. *Journal of psychedelic studies*, 2(1), 53-60.
- Ona, G., & Bouso, J. C. (2020). Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review. *Neuroscience & Biobehavioral Reviews*, 119, 194-203.
- Palmer, M., & Maynard, O. M. (2022). Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. *Harm reduction journal*, 19(1), 81.
- Pearson, M. R. (2013). Use of alcohol protective behavioral strategies among college students: A critical review. *Clinical psychology review*, 33(8), 1025-1040.
- Pedersen, E. R., Hummer, J. F., Rinker, D. V., Traylor, Z. K., & Neighbors, C. (2016). Measuring protective behavioral strategies for marijuana use among young adults. *Journal of studies on alcohol and drugs*, 77(3), 441-450.
- Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., ... & Carhart-Harris, R. L. (2022). Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. *Journal of Psychopharmacology*, 36(1), 31-45.
- Psychedelic Alpha (2025). Psychedelic Legalization & Decriminalization Tracker: psychedelicalpha.com/data/psychedelic-laws [Dostęp: 10/03/2025]
- Radoń, S. (2014). Kwestionariusz Ruminacji-Refleksyjności (polska adaptacja The Rumination-Reflection Questionnaire). *Psychoterapia*, 2(169), 61-72.
- Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019). Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. *Journal of psychopharmacology*, 33(9), 1076-1087.
- Rucker, J. J., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. *Neuropharmacology*, 142, 200-218.
- Schenberg, E. E. (2018). Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. *Frontiers in pharmacology*, 9, 733.
- Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. *Journal of Psychopharmacology*, 36(3), 258-272.
- Schultes, R. E. (1969). Hallucinogens of Plant Origin: Interdisciplinary studies of plants sacred in primitive cultures yield results of academic and practical interest. *Science*, 163(3864), 245-254.
- Sierosławski, J. (2020). *Używanie alkoholu i narkotyków przez młodzież szkolną. Raport z ogólnopolskich badań ankietowych zrealizowanych w 2015 r.* (Alcohol and drug use among school children. The ESPAD Polish report) Warszawa: Instytut Psychiatrii i Neurologii.
- Singer, E. O., & Schensul, J. J. (2011). Negotiating ecstasy risk, reward, and control: A qualitative analysis of drug management patterns among ecstasy-using urban young adults. *Substance use & misuse*, 46(13), 1675-1689.
- Sipowicz, K. (2013). *Encyklopedia polskiej psychodelii. Od Mickiewicza do Masłowskiej, od Witkacego do street artu*. Warszawa: Krytyka Polityczna.
- Soar, K., Turner, J. J. D., & Parrott, A. C. (2006). Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. *Journal of psychopharmacology*, 20(3), 417-424.
- Swanson, L. R. (2018). Unifying theories of psychedelic drug effects. *Frontiers in pharmacology*, 172.
- Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2024). The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item. *Psychiatric Medicine*, 2(1), 33-43.
- Swanson, L. R. (2018). Unifying theories of psychedelic drug effects. *Frontiers in pharmacology*, 9, 172.
- van Elk, M., & Yaden, D. B. (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. *Neuroscience & Biobehavioral Reviews*, 140, 104793.
- Vidal Gine, C., Fernández Calderón, F., & Lopez Guerrero, J. (2016). Patterns of use, harm reduction strategies, and their relation to risk behavior and harm in recreational ketamine users. *The American Journal of Drug and Alcohol Abuse*, 42(3), 358-369.
- Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients' accounts of increased "connectedness" and "acceptance" after psilocybin for treatment-resistant depression. *Journal of humanistic psychology*, 57(5), 520-564.
- Więckiewicz, G., & Pudło, R. (2021). Wyniki ogólnopolskiej ankiety „PolDrugs 2021”—kim są polscy użytkownicy substancji psychoaktywnych?. *Psychiatria/Psychiatria*, 18(2).
- Winstock, A.R., Timmerman, C., Davies, E., Maier, L.J., Zhuparris, A., Ferris, J.A., Barratt, M.J., Kuypers, K.P.C. (2021). Global Drug Survey 2020. Psychedelics: Key Findings Report. www.drugsandalcohol.ie/33864/1/GDS2020-Psychedelics-report.pdf
- Wood, M. J., McAlpine, R. G., & Kamboj, S. K. (2024). Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study. *Scientific Reports*, 14(1), 28817.
- Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022). Preparing for the bursting of the psychedelic hype bubble. *JAMA psychiatry*, 79(10), 943-944.